| pubmed-article:9339257 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9339257 | lifeskim:mentions | umls-concept:C0003195 | lld:lifeskim |
| pubmed-article:9339257 | lifeskim:mentions | umls-concept:C0004239 | lld:lifeskim |
| pubmed-article:9339257 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:9339257 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:9339257 | pubmed:dateCreated | 1997-11-5 | lld:pubmed |
| pubmed-article:9339257 | pubmed:abstractText | 1/1 atrial tachycardia or "quinidine" flutter under class I antiarrhythmic drugs is a serious complication of these agents which, unfortunately, cannot be anticipated. The aim of this study was to review the cases of 11 patients who had suffered this complication of class I antiarrhythmic therapy to see if it could have been prevented. All drugs of this class were included. The 11 subjects were aged 57 to 78: 7 had no apparent underlying cardiac disease and the others had valvular (n = 1), hypertensive (n = 1) and ischaemic (n = 2) heart disease. They were treated for episodes of paroxysmal atrial fibrillation or tachycardia. In the absence of treatment, 7 patients had a short PR interval on the ECG (PR between 0.11 and 0.14 s). In the other 4, the PR interval was normal (0.16 to 0.20 s), but the P wave was widened with appearances of left atrial hypertrophy or an intra-atrial conduction defect. High amplification ECG performed in 3 patients showed continuity of atrial and ventricular depolarisation. Atrial stimulation showed excellent nodal conduction with a Wenckebach point of 200/min. The authors conclude that a short PR interval is predisposing factor to 1/1 atrial tachycardia with class I antiarrhythmics. High amplification ECG which allows identification of the end of the P wave with respect to the QRS complex could help identify subjects at risk when the P wave is widened and that, consequently, the PR interval appears to be normal. | lld:pubmed |
| pubmed-article:9339257 | pubmed:language | fre | lld:pubmed |
| pubmed-article:9339257 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9339257 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9339257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9339257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9339257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9339257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9339257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9339257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9339257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9339257 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9339257 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:9339257 | pubmed:issn | 0003-9683 | lld:pubmed |
| pubmed-article:9339257 | pubmed:author | pubmed-author:LouisPP | lld:pubmed |
| pubmed-article:9339257 | pubmed:author | pubmed-author:DanchinNN | lld:pubmed |
| pubmed-article:9339257 | pubmed:author | pubmed-author:BeurrierDD | lld:pubmed |
| pubmed-article:9339257 | pubmed:author | pubmed-author:Brembilla-Per... | lld:pubmed |
| pubmed-article:9339257 | pubmed:author | pubmed-author:Terrier de... | lld:pubmed |
| pubmed-article:9339257 | pubmed:author | pubmed-author:HouplonPP | lld:pubmed |
| pubmed-article:9339257 | pubmed:author | pubmed-author:JacqueminLL | lld:pubmed |
| pubmed-article:9339257 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9339257 | pubmed:volume | 90 | lld:pubmed |
| pubmed-article:9339257 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9339257 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9339257 | pubmed:pagination | 961-6 | lld:pubmed |
| pubmed-article:9339257 | pubmed:dateRevised | 2009-2-13 | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:meshHeading | pubmed-meshheading:9339257-... | lld:pubmed |
| pubmed-article:9339257 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9339257 | pubmed:articleTitle | [Can 1/1 atrial flutter be foreseen by class I anti-arrhythmics?]. | lld:pubmed |
| pubmed-article:9339257 | pubmed:affiliation | Service de cardiologie A, CHU de Brabois, Vandoeuvre. | lld:pubmed |
| pubmed-article:9339257 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9339257 | pubmed:publicationType | English Abstract | lld:pubmed |
